SCHEMBL19862556

SCHEMBL19862556

Cc1ccnc(CNC(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
UHRF1 Q96T88 1/20 0.42
CCR1 P32246 1/20 0.42
CCR5 P51681 1/20 0.42
CCR8 P51685 1/20 0.42
NOS2 P35228 2/20 0.40
KDM4E B2RXH2 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
POLB P06746 2/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 1/20 0.38
HIF1A Q16665 1/20 0.38
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
HTR1A P08908 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27284222 0.80 KCNH2 (0.38) KDM4EKMT2AADRA2C
SCHEMBL23015680 0.80 BACE1 (0.37) MEN1KMT2AALDH1A1HIF1AADRA2C
SCHEMBL10061638 0.79 KDM1A (0.49) KDM1AMAOAMAOBUHRF1CCR1
SCHEMBL16574997 0.77 SIRT2 (0.50) MAOAMAOBKDM4EALDH1A1
SCHEMBL13167405 0.76 TRPV3 (0.45) NOS2NOS3ALDH1A1ADRB2
SCHEMBL2259096 0.76 KDM1A (0.47) KDM1AMAOAMAOBUHRF1CCR1
SCHEMBL17886852 0.76 KDM1A (0.47) KDM1AMAOAMAOBUHRF1CCR1
SCHEMBL6920045 0.75 NOS1 (0.48) KDM1AMAOAMAOBUHRF1CCR1
SCHEMBL29851521 0.75 NOS1 (0.48) KDM1AMAOAMAOBUHRF1CCR1
SCHEMBL25044387 0.74 RAB9A (0.44) KDM1AMAOAMAOBNOS2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126777-A1 HETEROAROMATIC COMPOUNDS ASTRAZENECA AB (SE) 2024-06-20 WO disclosed
US-20190233441-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-08-01 US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044343-A1 BICYCLIC IMIDAZOLO DERIVATIVE PDE3A, PDE2A, PDE5A KDM1A 1448/4885MAOA 132/4885MAOB 210/4885
US-20190233441-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 KDM1A 1215/4885MAOA 959/4885MAOB 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.